Furolax

Quick links to important sections

Furolax

Method of action: Antidiarrheal, Antiprotozoal

Treatment option: Diarrhea, Dysentery, Enteritis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furolax

What is Furolax? A Foundational Overview

The drug Furolax is a commercial preparation containing the active ingredient Furazolidone, a prescription-only synthetic antimicrobial agent used specifically for localized infections of the digestive tract.

Property Description
Active ingredient Furazolidone (INN)
Form Tablets or Oral Suspension
Pharmacological class Nitrofuran Antibiotic, Antiprotozoal Agent
General purpose Resolves localized gastrointestinal infections
Origin Synthetic (Oxazolidine derivative)

1. What Type of Medicine is Furolax? (Definition and Classification)

Furolax is fundamentally a synthetic antimicrobial agent containing the active substance Furazolidone, which is classified as a nitrofuran antibiotic. This distinct chemical class, derived from the oxazolidine derivative structure, separates it from many common antibiotics. Furazolidone holds an established classification as both an antibacterial drug and an antiprotozoal agent, reflecting its broad-spectrum capability to target both bacteria and single-celled protozoa. This dual efficacy is clinically recognized for its use in addressing microbial imbalances that cause diarrheal illnesses.

2. Composition and Presentation of Furazolidone (Form and Composition)

The medicine's composition is a single-ingredient formulation, delivering only Furazolidone (C8H7N3O5). It is manufactured for oral administration, typically supplied as solid tablets or a liquid oral suspension. The oral route ensures that the primary concentration of the drug is delivered directly into the gastrointestinal tract, concentrating its therapeutic action where the infection is present. This preparation is designated as a prescription-only medication, indicating that its specific use requires professional medical oversight.

3. General Purpose of this Antimicrobial Agent (High-Level Benefit)

The overarching general purpose of this antimicrobial agent is to resolve localized gastrointestinal infections by achieving microbicidal action against the causative pathogens. The drug interferes with key enzyme systems within the target organisms, causing metabolic disruption, which actively results in the death of the microorganism. Pharmacological studies confirm that this mechanism contributes to a relatively low frequency of acquired microbial resistance compared to some other antibiotic classes. The drug’s utility is therefore linked to its ability to decisively eliminate various gut pathogens, providing effective relief from the microbial cause of digestive system distress.

Regulatory References

  1. Mayo Clinic Drug Information

What side effects are possible with Furolax?

Possible Side Effects and Safety Information

The active ingredient in Furolax, Furazolidone, is associated with documented adverse reactions classified by the systems they affect, as noted in official regulatory documents. These effects range from commonly reported occurrences to specific safety considerations for vulnerable populations.


Documented Adverse Reaction Scope

Adverse reactions are primarily associated with the gastrointestinal system (nausea, vomiting, diarrhea, abdominal pain) and the nervous system (headache, dizziness, weakness, malaise), often classified as occasional or less common in regulatory summaries. Hypersensitivity reactions (such as fever, joint pain, or skin rash) are also documented, along with the expected, medically insignificant side effect of dark yellow to brown discoloration of the urine.


Serious Safety Considerations

The medicine is associated with several serious safety constraints and potential reactions that require specific caution:

  • Monoamine Oxidase Inhibition (MAOI) Risk: Furazolidone possesses MAOI activity, creating a risk of Hypertensive Crisis if used in excess of recommended doses/duration or taken concurrently with tyramine-containing foods or certain sympathomimetic medicines.
  • Alcohol Reaction: The consumption of alcohol during therapy and for at least four days after stopping the drug is explicitly restricted due to the potential for a Disulfiram-Like Reaction (flushing, difficulty breathing, chest constriction).
  • Hemolytic Anemia: The medicine is not recommended for use in infants under one month of age due to the potential risk of causing severe hemolytic anemia. Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency may also experience mild, reversible hemolysis.

Regulatory documents also note evidence of tumorigenic activity in high-dose, chronic animal studies, which contributes to the drug’s overall safety profile.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation describes specific severe outcomes associated with furazolidone overdose, mandating immediate medical intervention. For any suspected or confirmed overexposure, it is required to seek immediate medical attention due to the potential for severe systemic and neurological toxicity.

Documented Overdose Manifestations

Overdose may present with intensified gastrointestinal symptoms, including nausea, vomiting, and diarrhea. More serious manifestations officially documented include adverse effects on the nervous system, such as polyneuritis and acute toxic psychosis, reflecting central nervous system involvement.

Required Emergency Management

No specific antidote is known for furazolidone overdose, as explicitly stated in regulatory information. Consequently, management is officially defined as symptomatic and supportive treatment, focusing on maintaining vital functions and addressing specific clinical signs. Hospitalization and observation may be necessary to manage severe effects.

High-Risk Considerations

The official profile highlights a population-specific risk: individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are at an increased and recognized risk of developing acute hemolysis—a potentially life-threatening destruction of red blood cells—following an overdose.

Therapeutic Uses of Furolax

Therapeutic Indications

Furolax is a medication primarily indicated for the treatment of constipation. It belongs to a class of drugs known as osmotic laxatives, which work by increasing the water content in the stool to facilitate easier passage and more frequent bowel movements.

Chronic and Occasional Constipation

The medication is used to manage both short-term episodes of constipation and more persistent, chronic conditions. By promoting fluid retention within the intestinal tract, it helps to soften the stool consistency, addressing difficulties associated with straining or infrequent evacuation.

Bowel Preparation

In certain clinical settings, Furolax is utilized for colonic lavage. This process involves a complete cleansing of the bowel to ensure the intestinal tract is clear. This is typically necessary prior to specific diagnostic procedures or surgical interventions, such as:

  • Endoscopic examinations (e.g., colonoscopy)
  • Radiological imaging of the gastrointestinal tract
  • Surgical procedures requiring an empty bowel

Mechanism of Action and Benefits

The primary benefit of Furolax is its predictable effect on bowel motility without being absorbed into the bloodstream.

  • Hydration of Stool: It draws water into the colon, which increases stool volume and triggers natural intestinal movement.
  • Non-Systemic Action: Because the active components are not significantly absorbed by the body, the action remains localized within the digestive system.
  • Restoration of Regularity: For individuals with chronic motility issues, it helps establish a more consistent rhythm for waste elimination.

Regulatory References

  1. National Cancer Institute Drug Dictionary entry for furazolidone

Eligibility and Restrictions for Use

Eligibility and Contraindications for Furolax (Furazolidone)

Official regulatory documents define strict criteria for the use of Furolax, primarily based on patient age, concurrent medication, and specific medical conditions.

Absolute Prohibitions (Contraindications)

Contraindicated Group
Infants under 1 month of age (due to risk of hemolytic anemia)
Patients with known hypersensitivity to Furazolidone or other nitrofuran drugs
Patients taking Monoamine Oxidase Inhibitors (MAOIs)
Patients consuming alcohol during or within four days after treatment
Patients consuming high levels of tyramine-containing foods or indirectly-acting sympathomimetic amines

Restricted or Conditional Use

Age-Group Eligibility: Adults and children 1 month of age and over are generally eligible. Use in older adults (geriatric) is considered not specifically established as comparative data is lacking in official labeling.

Comorbidity Restrictions: Patients with Glucose-6-phosphate dehydrogenase (G6PD) deficiency require caution and close monitoring due to the potential for mild, reversible hemolysis. Caution is also advised for patients with existing renal (kidney) or hepatic (liver) impairment.

Maternal Status: Use during pregnancy is classified with caution (Category C or equivalent) and is permitted only if the regulatory benefit outweighs the risk, as safety is not established. The drug is not recommended for women breastfeeding infants under 1 month old.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Furolax


Interaction Scope

Category Official Regulatory Documentation
Medicinal products and food categories with documented interactions Other Monoamine Oxidase (MAO) Inhibitors, Indirectly-acting Sympathomimetic Amines, CNS Depressants (e.g., Sedatives, Narcotics), Hypoglycaemic Agents, Alcohol (Ethanol), and Tyramine-containing foods.
Mechanistic basis of interactions (as stated in label) Inhibition of the Monoamine Oxidase (MAO) enzyme system; Pharmacodynamic potentiation of CNS depression; Potentiation of hypoglycaemic effects.
Interaction severity and restrictions Co-administration with MAO Inhibitors, Sympathomimetics, Tyramine-containing foods, and Alcohol is formally contraindicated due to the risk of severe hypertensive reactions or a disulfiram-like effect.
Timing-based separation rules Alcohol/Ethanol must be avoided during therapy and for at least four days after discontinuation. MAO-active agents and Tyramine-containing foods must be avoided for at least two weeks (14 days) after discontinuation.
Population-specific interaction notes The drug is contraindicated in Infants under 1 month of age. Caution is required for patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency due to documented risk of hemolytic anemia.

Connection to the overall interaction profile

The regulatory interaction structure is primarily defined by the drug's effect as a Monoamine Oxidase Inhibitor, establishing extensive contraindications with other MAO-active agents and specific dietary components. This mechanism dictates mandatory timing separation rules (e.g., two weeks post-therapy avoidance) and governs the overall clinical risk profile as detailed in official government documentation.

Mechanism of Action

How Furolax Works: The Mechanism of Action

The function of Furazolidone (Furolax) relies on a selective microbicidal mechanism executed within the gastrointestinal tract. The drug is a prodrug that requires specific nitroreductase enzymes present in the target pathogens for its activation. This essential enzymatic reduction converts Furazolidone into highly reactive intermediates (nitroso and hydroxylamine derivatives).

These activated metabolites act as cytotoxins, chemically attacking and cross-linking the microbial DNA and RNA. This irreversible damage completely obstructs DNA replication and transcription, initiating a cascade that leads to the cessation of cellular function.

Simultaneously, the intermediates interfere with multiple essential microbial enzyme systems responsible for metabolism and energy production, compounding the cellular toxicity and microbicidal action. This dual attack on both genetic integrity and metabolic homeostasis results in the physiological consequence of elimination of target pathogens from the GI environment. The mechanism is constrained by the required step of nitroreductase activity; impaired enzyme function is the biological basis for mechanistic resistance in certain organisms.

Dosage and Administration Information

How to Use Furolax (Furosemide) – Administration Guidelines

This section outlines the usage of furosemide including routes of administration, dosing parameters, and preparation requirements.


Routes and Dosage

Feature Administration Details
Route of Administration Oral (tablet or solution), Intravenous (IV injection or infusion), or Intramuscular (IM injection).
Standard Oral Dosing The initial adult dose is typically 20 mg to 80 mg as a single dose. Subsequent doses may be increased by 20 mg to 40 mg and are separated by 6 to 8 hours.
Standard IV/IM Dosing The initial dose is usually 20 mg to 40 mg. If necessary, a subsequent dose may be administered 2 hours after the first dose.

Administration Conditions

  • Timing: Oral furosemide can be taken with or without food. Taking it in the morning or early afternoon is often recommended to avoid disrupting sleep with frequent urination.
  • Preparation: Tablets must be swallowed whole. The oral solution requires measurement with a calibrated device. Intravenous injection must be administered slowly, over 1 to 2 minutes.
  • Age-Specific Rules: Dosing for pediatric patients is based on body weight (mg/kg), and the maximum single dose generally should not exceed 6 mg/kg. Lower starting doses may be appropriate for the elderly.

Procedural Protocol

Parenteral administration (IV/IM) is typically replaced by oral administration as soon as clinical status permits. If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Furolax

The research for Furolax (which contains the active ingredient Furazolidone) includes studies where it was evaluated in settings involving infectious causes of gastrointestinal distress. Official evaluations rely on clinical trials that monitored the elimination of the causative organisms and the simultaneous measurement of changes in a patient's symptoms. The findings reported below describe group patterns observed in these studies, not personal outcomes, and research does not determine whether an individual will respond similarly.


Evidence for Use in Giardiasis (Intestinal Protozoal Infection)

Furolax was studied for the management of Giardiasis, a condition involving a protozoal infection in the intestine. The evidence base includes Randomized Controlled Trials (RCTs) and comparative clinical trials. Research examined parasitological outcomes, checking for the absence of the parasite, and clinical outcomes, which assessed patient-reported outcomes describing discomfort from symptoms like diarrhea. These studies primarily involved children and adults with confirmed infection.

Findings describe patterns observed in the studies where cohorts treated with the drug were monitored for parasite elimination at short-term follow-up points. Some comparative trials described patterns of clearance rates that were monitored in the context of other non-placebo regimens. However, the specific clearance rates reported varied across the studies, which often used different treatment durations.


What Is Still Uncertain About Furolax Research

Evidence quality varies across studies, with many key trials being several decades old, meaning they may not fully reflect the current scientific understanding or microbial environment. Comparative evidence is lacking against the most modern anti-infective agents used today. Additionally, follow-up durations were limited across the board, so the long-term impact on overall digestive health is not fully established.

Frequently Asked Questions (FAQ)

Common questions about Furolax (FAQ)


Q: What happens if I forget to take a dose of Furolax?

Official instructions state that if a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped. The usual dosing schedule should then be resumed.


Q: Are there any specific foods to avoid when taking Furolax?

Yes, official regulatory documents formally contraindicate co-administration with high levels of tyramine-containing foods. This is because the drug can act as a Monoamine Oxidase Inhibitor (MAOI), and combining it with tyramine-rich foods creates the risk of a severe hypertensive reaction.


Q: Can Furolax interact with common pain relievers?

Due to the drug's MAOI activity, caution is required when it is used alongside CNS depressants, which can include some narcotic pain relievers. Regulatory sources also indicate that some common over-the-counter pain medications may have documented interactions. Professional review of all medication combinations is a standard regulatory caution.


Q: Is it safe to take Furolax with vitamins or supplements?

Official documentation does not provide a complete list of all vitamins or supplements, but certain herbal products and other supplements that act as indirectly-acting sympathomimetic amines are contraindicated. Regulatory guidance suggests a professional review of all supplements and herbal products prior to initiating therapy.


Q: Can people with kidney issues use Furolax?

Regulatory documents advise caution for patients who have existing renal (kidney) impairment. The official information indicates that use in these cases may require close professional monitoring.


Q: Can people with liver impairment use Furolax?

Official product information advises caution for patients with existing hepatic (liver) impairment. This group is typically managed with professional supervision and close monitoring during treatment.


Q: What pregnancy category is Furolax classified under?

Official regulatory documents often classify the drug's use during pregnancy under Category C or its equivalent. This classification indicates that safety is not established, and the drug is only used if the potential benefit is deemed to outweigh the potential risk.


Q: What are the typical storage conditions mentioned for Furolax?

Official guidelines state that the medicine must be stored at room temperature, which is typically 15 C to 30 C (59 F to 86 F). It must be kept in a tightly sealed container, away from heat, moisture, and direct light, and stored out of the reach of children.


Q: Can Furolax cause long-term problems?

Official safety documents note evidence of tumorigenic activity in high-dose, chronic animal studies, which is included in the official safety profile documentation. The medicine’s MAOI effect also creates the risk of hypertensive crisis if it is used in excess of recommended dosage or duration.


Q: What should I do if I experience an unusual side effect from Furolax?

Official documents typically recommend that individuals consult a professional if they experience any severe side effects or a worsening of existing symptoms. Reporting protocols are designed to ensure safety monitoring.


Q: What kind of studies have been done on Furolax?

The evidence base summarized in official research documents includes Randomized Controlled Trials (RCTs) and comparative clinical trials. These studies have primarily focused on examining parasitological outcomes (parasite elimination) and clinical outcomes (symptom relief) in both children and adults.


Q: Is Furolax a brand name or a generic name?

Furolax is the name of a commercial preparation (brand name) that contains the active ingredient, Furazolidone. Furazolidone is the generic name of the active chemical substance.


Q: Does Furolax contain any common allergens, like lactose or gluten?

The exact ingredients (excipients) in a specific tablet or oral suspension formulation can vary. Official patient labeling advises checking the product ingredients for specific common allergens like lactose or gluten, especially if sensitivities are known.


Q: Can Furolax be cut in half or crushed?

The regulatory guidelines for the oral tablets instruct that they must be swallowed whole. The tablets should not be cut, crushed, or modified to ensure the intended therapeutic action and rate of absorption.


Q: Does Furolax affect my ability to drive?

Because common side effects include nervous system issues like headache and dizziness, official warnings mention the need for caution before driving or operating machinery.


Q: Can I take Furolax if I have diabetes?

The medicine has documented interactions with hypoglycaemic agents, such as insulin and certain oral diabetes drugs. The interaction creates a risk of potentiation of hypoglycaemic effects, which is why official documents advise caution.


Q: What is the official definition of the condition Furolax treats?

Furolax was studied for the management of Giardiasis, which is defined in the evidence base as an infection in the intestine caused by a single-celled protozoal parasite. The drug's classification allows it to target this type of infection.


Q: Are there any warnings about combining Furolax with herbal teas?

Regulatory documents advise that certain herbal products can interact with Furolax, often due to its MAOI properties. A professional review of all teas and supplements is necessary prior to use to ensure no contraindicated substances are consumed.


Q: Is there a maximum recommended duration for using Furolax?

Yes, regulatory documents specify a typical limited duration of use that is dependent on the infection being treated. For example, use may be specified as five to seven days for bacterial diarrhea or seven to ten days for giardiasis.


Q: Does Furolax need to be taken at a specific time of day?

Regulatory instructions state that while the drug can be taken with or without food, taking it in the morning or early afternoon is often recommended. The rationale in the labeling for this timing is often based on the overall administration regimen.


Q: Do I need to change my diet while on Furolax?

Yes, regulatory documents establish formal contraindications with certain foods and beverages, requiring patients to adhere to specific dietary restrictions. The co-administration of tyramine-containing foods and alcohol (ethanol) is formally contraindicated.


Q: What does the patient information leaflet say about overdose?

Official information warns that the risk of a hypertensive crisis (a dangerous rise in blood pressure) is linked to taking the medicine in doses larger than recommended or for longer than the typical duration. Overdose is also associated with severe gastrointestinal distress.


Q: Is Furolax available in different strengths?

Yes, the medicine is manufactured as different physical forms, including both tablets and a liquid oral suspension. These forms are available in specific dosage strengths for administration.


Q: What should I know about stopping Furolax after long-term use?

Due to the drug's MAOI activity, the mandatory avoidance rules for certain MAO-active agents and tyramine-containing foods must be followed for at least two weeks (14 days) after the therapy has been discontinued.


Q: Does taking Furolax affect routine blood tests?

Due to the documented potential for a reaction called hemolytic anemia in susceptible individuals, blood tests may be necessary for professional monitoring. This is particularly important for patients with a condition called Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.


Q: Are there specific guidelines for elderly patients using Furolax?

Regulatory documents advise that lower starting doses may be appropriate for the elderly population. However, official labeling notes that specific comparative data for use in this age group is not specifically established.

How should Furolax be stored and disposed of?

How to Store and Dispose of Furolax?

Furolax (Furazolidone) must be stored strictly according to official regulatory requirements to maintain its stability.


️ Storage Requirements

Condition Requirement
Temperature Store at room temperature, typically 15 C to 30 C (59 F to 86 F).
Environment Keep the medicine away from heat, moisture, and direct light.
Container Store in a closed, tightly sealed container.
Handling Keep from freezing and do not keep outdated medicine.
Safety Keep out of the reach of children.

️ Disposal Instructions

Furolax is not on the FDA flush list and should not be poured down the drain. Official guidelines recommend using a drug take-back program. If this is unavailable, remove the medicine from its original container, mix it with an undesirable substance, place it in a sealed bag, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furolax found in:

A-Z Index: